XML 20 R10.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype® tests. The services are considered completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended March 31,
(In thousands)20252024
Screening
Medicare Parts B & C$201,682 $173,790 
Commercial284,233 254,143 
Other54,092 46,865 
Total Screening540,007 474,798 
Precision Oncology
Medicare Parts B & C$46,207 $48,050 
Commercial48,270 46,700 
International51,588 44,533 
Other20,713 23,443 
Total Precision Oncology166,778 162,726 
Total$706,785 $637,524 
Screening revenue primarily includes laboratory service revenue from Cologuard and Prevention Genetics, LLC tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1% of revenue recorded in the Company’s condensed consolidated statement of operations for the three months ended March 31, 2025 and 2024.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not significant as of March 31, 2025 and December 31, 2024.
Revenue recognized for the three months ended March 31, 2025 and 2024 that was included in the deferred revenue balance at the beginning of the period was not significant.